Heart failure patients with cardiac amyloidosis are at higher risk of mortality and readmission after acute heart failure: A case control study from ICREX-94

Berthelot, E.; Broussier, Amaury; Hittinger, Luc; Belmin, J; David, Jean‐Philippe; Genet, Bastien; Damy, Thibaud

doi:10.1016/j.acvdsp.2022.10.096

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Not only is AF a common cause of decompensation leading to acute heart failure in ATTR-CA, leading to increased hospitalization and death in some cases; AF also increases the risk of embolic stroke, which puts the patients at ongoing risk for further loss of functions. 28,29 Apart from CA, CAD by itself is an independent risk factor for AF which advances the degree of focal ectopic activity. 30 Sometimes, the incidence of AF varies in different races for cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…Acute heart failure, which is precipitated by restrictive cardiomyopathy and AF in CA, elevates the degree of severity, impacting hospitalization requirements and adding to procedural management complexity, which ultimately leads to an increased economic burden. 29 Heart failure readmissions and further interventions like left ventricular assist devices, if needed, add to the healthcare cost. 34,35 In theorem, coronary revascularization complications, which include pulmonary edema and cardiogenic shock, could occur more frequently in CA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of amyloidosis on the outcomes of patients with coronary artery disease: A nationwide analysis

Prakash Babu,

Layadi,

Singh

et al. 2024

F1000Res

View full text Add to dashboard Cite

Background: Amyloidosis is a disease of increasing interest, primarily due to its high prevalence and advances in diagnostic and therapeutic options. It is known to be coexistent with a significant number of aortic stenosis patients (AS). Various studies have been done to evaluate its role in the clinical outcomes of AS. However, there is a lack of similar data on coronary artery disease (CAD) patients. Methods: We conducted a cross-sectional cohort study using the nationwide inpatient sample (NIS) 2018–19. We included 305,675 adult inpatients with CAD and further divided by the presence of a co-diagnosis of amyloidosis. A logistic regression model was used to evaluate the odds ratio (OR) of the association between in-hospital mortality in CAD inpatients with and without amyloidosis and other comorbidities. Results: The prevalence of amyloidosis in the total inpatient population with CAD was 7.3%, with the majority of the patients being in the older age group (mean age: 66.88 years), males (64.2%), and white (70.9%). Interestingly, the amyloidosis cohort had a higher prevalence of hypertension (89.3% vs. 85.1%). CAD inpatients with amyloidosis were noted to have higher in-hospital mortality (1.6% vs. 0.9%) with an OR of 1.87 (95% CI 1.66–2.11, p <0.001). These patients also had a higher length of stay (6.66 days vs. 4.68 days), total charges ($156,149.76 vs. $119,442.71), and major loss of function (56.5% vs. 30.5%). Amongst patients with CAD and amyloidosis, household income below the 50th percentile was a risk factor for in-hospital mortality (OR 1.5, 95% CI 1.39–1.63, p <0.001). Conclusions: Results from our study show that CAD inpatients who have comorbid amyloidosis have worse outcomes compared to those who do not. Further studies are needed to determine the etiology behind these outcomes and thus guide the management of stable CAD in amyloidosis patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of amyloidosis on the outcomes of patients with coronary artery disease: A nationwide analysis

Prakash Babu,

Layadi,

Singh

et al. 2024

F1000Res

View full text Add to dashboard Cite

show abstract

“…Cardiac amyloidosis is an under‐diagnosed cause of HF and has a worse prognosis than other forms of HF: It is associated with a three‐fold greater risk of death and a two‐fold greater risk of all‐cause hospital readmission 90 days after discharge 10 …”

Section: Risk Factors and Preventionmentioning

confidence: 99%

Editors' highlight picks from 2023 in ESC heart failure

Bäck,

von Haehling,

Papp

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

Heart failure is a devastating syndrome affecting an increasingly high number of patients worldwide. Its aetiology and pathogenesis are complex with the involvement of factors ranging from the genetic material through valvular dysfunctions to numerous organs beyond the entire cardiovascular system. Based on continuous efforts of the heart failure scientific community we have witnessed major advances in many related disciplines during the last year. For example, epidemiological aspects—paving the road for improved risk prevention—have been thoroughly analysed for various geographical regions. Additionally, evidence‐based approaches now allow the introduction of novel guideline recommended medical therapies (i.e. sodium‐glucose transporter 2 inhibitors, and iron supplementation) while basic and translational research aim to explore additional molecular targets for future heart failure diagnostics and medications. All above aspects are addressed in this article, where a selection of articles published in the ESC Heart Failure journal in 2023 are highlighted. The editors are confident that the scientific contributions of ESC Heart Failure effectively served a highly relevant area of cardiovascular research last year.

show abstract

Heart failure patients with cardiac amyloidosis are at higher risk of mortality and readmission after acute heart failure: A case control study from ICREX-94

Cited by 2 publications

References 0 publications

Impact of amyloidosis on the outcomes of patients with coronary artery disease: A nationwide analysis

Impact of amyloidosis on the outcomes of patients with coronary artery disease: A nationwide analysis

Editors' highlight picks from 2023 in ESC heart failure

Contact Info

Product

Resources

About